Stock Details
4523.T is Eisai Co., Ltd.'s stock. Stock exchange Tokyo (Currency JPY). Average price in 50 days is 6,034.80๏ฟฅ. Average daily volumn in 3 months 1.15M. Market cap 2.22T

Stock symbol : 4523.T. Exchange : Tokyo. Currency : JPY
Lastest price : 7,749.00๏ฟฅ. Total volume : 14.98M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Eisai Co., Ltd. (4523.T)
Last Price

Previous Close7,704.00
Day Range7,380.00-8,100.00
Bid7,650.00 x N/A
Ask7,750.00 x N/A
Average Volume1.15M
Market Cap2.22T
52 Week Range5,011.00-8,486.00
Trailing P/E46.33
Foward P/E41.83
Dividend (Yield %)2.06%
Ex-Dividend Date2023-03-30

Financial Details

According to Eisai Co., Ltd.'s financial reports the company's revenue in 2022 were 756.23B an increase( +17.21%) over the years 2021 revenue that were of 645.94B. In 2022 the company's total earnings were 47.95B while total earnings in 2021 were 42.12B( +11.9%).

Loading ...


Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted... medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.


Market Cap:
Total Assets:
Total Cash:

News about "Eisai Co., Ltd."


Alzheimer's drug study yields positive results, say makers Eisai and Biogen

Source from : Reuters - 2 days ago

An experimental Alzheimer's drug developed by Eisai Co Ltd and Biogen Inc significantly slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, the ...See details»


Analysis-Eisai's Trial Success Raises Hope For Alzheimer's Prevention

Source from : International Business Times - 1 days ago

Clear evidence this week that Eisai and Biogen's drug lecanemab slows cognitive decline in early stage dementia has galvanized efforts among Alzheimer's researchers toward a tantalizing goal - ...See details»


Positive results from Eisai and Biogen Alzheimerโ€™s trial

Source from : labiotech - 2 days ago

Eisai and Biogen have announced positive results from a trial of lecanemab to treat mild cognitive impairment due to Alzheimerโ€™s disease.See details»


Biogen, Eisai Stocks Soar On Landmark Alzheimer's Data, Lifting Rivals

Source from : International Business Times - 3 days ago

Shares in Biogen and Eisai soared on Wednesday reflecting the surprise trial success of their experimental Alzheimer's drug, which also lifted the stocks of rival drugmakers Roche and Eli Lilly.See details»


Eisaiโ€™s Alzheimer Success Leaves Many Questions Still Unanswered

Source from : Bloomberg on MSN - 3 days ago

Shares of Eisai Co. and partner Biogen Inc. have soared since reporting that their drug lecanemab slowed Alzheimerโ€™s, the first to unambiguously impede the progression of the disease in a final-stage ...See details»

Eisai (OTCMKTS:ESALY) Upgraded to Equal Weight by Morgan Stanley

Source from : Defense World - 2 days ago

Morgan Stanley upgraded shares of Eisai (OTCMKTS:ESALY โ€“ Get Rating) from an underweight rating to an equal weight rating in a research note published on Wednesday morning, The Fly reports. Eisai ...See details»


Alzheimer's drug succeeds in slowing cognitive decline, makers Eisai and Biogen say

Source from : YAHOO!News - 4 days ago

Eisai Co Ltd and Biogen Inc on Tuesday said their experimental Alzheimer's drug significantly slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, ...See details»


Eisai's Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint

Source from : Asia One - 4 days ago

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced positive topline results from Eisai's large global Phase 3 confirmatory Clarity AD clinical trial of lecanemab (development code: BAN2401), ...See details»


Alzheimer's disease: Eisai and Biogen release milestone data

Source from : biopharma-reporter - 3 days ago

An investigational Alzheimer's drug made by Eisai Co Ltd and Biogen slowed cognitive and functional decline in a trial involving a large group of patients in the early stages of the disease.See details»

Factbox: Eisai-Biogen Alzheimer's drug success follows many failures

Source from : Reuters - 4 days ago

Eisai Co Ltd and Biogen Inc reported from their Alzheimer's disease drug lecanemab that showed it significantly slowed cognitive decline, a big win for patients after a long string of failures to find ...See details»

ESALY Eisai Co., Ltd.

Source from : Seeking Alpha - 11 days ago

To ensure this doesnโ€™t happen in the future, please enable Javascript and cookies in your browser. Is this happening to you frequently? Please report it on our ...See details»


Alzheimer's drug proves effective in slowing symptoms: Eisai

Source from : pna - 3 days ago

Japanese drug maker Eisai Co. said Wednesday its Alzheimer's disease drug under development with US firm Biogen Inc. has proved to be effective in slowing aggravation of symptoms in a clinical ...See details»

Biogen And Eisai's Lecanemab Slows Progression Of Alzheimer's Disease In Phase 3 Trial

Source from : Nasdaq - 4 days ago

Biogen Inc. (BIIB) and Eisai Co., Ltd.'s investigational Alzheimer's disease drug lecanemab could potentially slow the progression of the disease in a large global Phase 3 clinical trial, the ...See details»

Eisai: Metoject Subcutaneous Injection Syringe (Methotrexate) Approved in Japan for Rheumatoid Arthritis

Source from : MarketWatch - 5 days ago

The approval is based on the results of a Phase III clinical trial (MC-MTX.17/RA) conducted in Japan by nippon medac to compare the efficacy and safety of Metoject with that of oral MTX, which ...See details»